Boron Neutron Capture Therapy
GPTKB entity
Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:cancer
|
| gptkbp:abbreviation |
gptkb:BNCT
|
| gptkbp:clinicalTrialPhase |
gptkb:Finland
gptkb:Japan gptkb:United_States |
| gptkbp:deliveryAgent |
boronophenylalanine (BPA)
sodium borocaptate (BSH) |
| gptkbp:developedBy |
gptkb:United_States
|
| gptkbp:effect |
localized radiation damage
minimal damage to surrounding tissue selective cell destruction |
| gptkbp:goal |
targeted tumor cell destruction
|
| gptkbp:hasResearchCenter |
gptkb:Osaka_Medical_College
gptkb:Brookhaven_National_Laboratory gptkb:Helsinki_University_Hospital |
| gptkbp:limitation |
boron delivery specificity
neutron source availability treatment planning complexity |
| gptkbp:mechanismOfAction |
alpha particle emission
lithium nucleus emission nuclear reaction between boron-10 and thermal neutrons |
| gptkbp:method |
neutron irradiation
boron-10 compound administration |
| gptkbp:proposedBy |
1936
|
| gptkbp:regulates |
FDA (in the US, investigational)
|
| gptkbp:relatedTo |
gptkb:radiation_therapy
gptkb:proton_therapy neutron therapy |
| gptkbp:requires |
gptkb:nuclear_reactor
imaging dosimetry treatment planning boron delivery agent patient selection |
| gptkbp:sideEffect |
alopecia
radiation injury mucositis skin erythema |
| gptkbp:status |
experimental
|
| gptkbp:treatment |
binary cancer therapy
targeted radiotherapy |
| gptkbp:usedFor |
gptkb:glioblastoma
gptkb:melanoma brain tumors recurrent head and neck cancer |
| gptkbp:bfsParent |
gptkb:BNCT
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Boron Neutron Capture Therapy
|